NBIX FY 2024 Earnings Report — Neurocrine Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

Neurocrine Biosciences, Inc.NBIX

FY 2024 Earnings

Reported February 10, 2025

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2024	Prior Q	FY 2023	QoQ Change	YoY Change
Revenue	$2.4B	—	$1.9B	—	24.8%
Op. Income	$571M	—	$251M	—	127.4%
Gross Margin	98.6%	—	97.9%	—	0.7pp
Net Margin	14.5%	—	13.2%	—	1.3pp
EPS (Diluted)	$3.29	—	$2.47	—	33.2%
Free Cash Flow	$557M	—	$362M	—	54.1%

Revenue Flow

Item	Amount
REVENUE	$2.4B
Cost of Revenue	$34M
GROSS PROFIT	$2.3B
R&D Expenses	$731M
Selling & Marketing	$191M
General & Administrative	$816M
SG&A Expenses	$1.0B
Other Expenses	$13M
Operating Expenses	$1.8B
Cost & Expenses	$1.8B
OPERATING INCOME	$571M
Interest Income	$91M
Interest Expense	$127M
Other Income/Expenses	-$85M
INCOME BEFORE TAX	$486M
Income Tax Expense	$145M
Net Income from Continuing Ops	$341M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$341M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$341M
D&A	$27M
EBIT	$613M
EBITDA	$640M
EPS	$3
EPS Diluted	$3

Income Statement

Item	Amount
REVENUE	$2.4B
Cost of Revenue	$34M
GROSS PROFIT	$2.3B
R&D Expenses	$731M
Selling & Marketing	$191M
General & Administrative	$816M
SG&A Expenses	$1.0B
Other Expenses	$13M
Operating Expenses	$1.8B
Cost & Expenses	$1.8B
OPERATING INCOME	$571M
Interest Income	$91M
Interest Expense	$127M
Other Income/Expenses	-$85M
INCOME BEFORE TAX	$486M
Income Tax Expense	$145M
Net Income from Continuing Ops	$341M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$341M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$341M
D&A	$27M
EBIT	$613M
EBITDA	$640M
EPS	$3
EPS Diluted	$3

Cash Flow Statement

Item	Amount
Net Income	$341M
Depreciation & Amortization	$27M
Stock-Based Compensation	$196M
Deferred Income Tax	-$123M
Other Non-Cash Items	$174M
Change in Working Capital	-$19M
OPERATING CASH FLOW	$595M
Capital Expenditure	-$38M
Acquisitions (Net)	$0
Purchases of Investments	-$1.1B
Sales/Maturities of Investments	$968M
Other Investing Activities	$0
NET CASH FROM INVESTING	-$127M
Net Debt Issuance	-$309M
Common Stock Repurchased	-$300M
Common Dividends Paid	$0
Other Financing Activities	$0
NET CASH FROM FINANCING	-$487M
FREE CASH FLOW	$557M
Net Change in Cash	-$18M

Balance Sheet

Item	Amount
Cash & Equivalents	$233M
Short-Term Investments	$843M
Net Receivables	$479M
Inventory	$57M
Other Current Assets	$112M
TOTAL CURRENT ASSETS	$1.7B
PP&E (Net)	$592M
Goodwill	$6M
Intangible Assets	$37M
Long-Term Investments	$864M
Tax Assets	$486M
Other Non-Current Assets	$10M
TOTAL NON-CURRENT ASSETS	$2.0B
TOTAL ASSETS	$3.7B
Account Payables	$110M
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$298M
TOTAL CURRENT LIABILITIES	$508M
Long-Term Debt	$0
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$166M
TOTAL NON-CURRENT LIABILITIES	$621M
TOTAL LIABILITIES	$1.1B
Common Stock	$100.0K
Additional Paid-In Capital	$2.6B
Retained Earnings	$29M
Treasury Stock	$0
Accum. Other Comp. Income	$6M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$2.6B
Minority Interest	$0
TOTAL EQUITY	$2.6B
TOTAL LIABILITIES & EQUITY	$3.7B
Total Debt	$455M
Net Debt	$222M